• LinkedIn
  • Twitter

Site Under Construction

Open Site Navigation

Mark Ledeboer, Ph.D., joined Expansion Therapeutics in June of 2021 as the Senior Vice President of Drug Discovery.  He previously served as Vice President, Head of Drug Discovery and Head of Chemistry at Goldfinch Bio where he successfully helped build and lead a multifunctional discovery project team that delivered and advanced the company’s lead asset, GFB-887, which is currently in Phase 2 development for focal segmental glomerulosclerosis.  Prior to his position with Goldfinch Bio, Dr. Ledeboer held roles of increasing responsibility in drug discovery at Vertex Pharmaceuticals, including as a research fellow in Medicinal Chemistry. Over the course of his career, Dr. Ledeboer has contributed to the discovery and development of multiple drug candidates, including decernotinib and pimodivir, and he is co-inventor on more than 20 patents.  Dr Ledeboer holds a Ph.D. and M.A. from Brown University where he studied synthetic organic chemistry, and he completed an NIH postdoctoral fellowship at The Scripps Research Institute in the laboratories of Dr Dale L Boger. He received his Bachelor of Science degree in Chemistry from Lafayette College.

Mark Ledeboer, PhD

Senior VP, Drug Discovery

  • LinkedIn

© 2021 Expansion Therapeutics     |    Terms of Use    |    Privacy Policy    |    info@expansionrx.com

LOCATIONS:

Headquarters

Boston, MA

Research

Jupiter, FL